Synairgen’s Hopes For Inhaled COVID-19 Therapy Dwindle
Hospital Study Fails
Executive Summary
The company is running out of chances for its inhaled interferon therapy after a Phase III study failed to show benefits for hospitalized COVID-19 patients.
You may also be interested in...
NIH Study Keeps Synairgen’s Dream Of An Inhaled COVID-19 Therapy Alive
SNG001 has moved into a Phase III open label trial in which it must prove its non-inferiority against Regeneron's monoclonal antibody cocktail.
Investor Faith In David Hung’s Nuvation Renewed By Anheart Buyout
The acquisition brings two potential best-in-class cancer therapies, which could make Nuvation a commercial company as soon as 2025.
Vertex Joins Regulus In Kidney Disease Therapy Hunt
The Boston, MA biotech is about to enter the clinic with its autosomal dominant polycystic kidney disease candidate but microRNA therapy pioneer Regulus is already setting the pace.